USPTO 2015–2025 USPTO PatentsView US Corporation

Roche Diabetes Care, Inc.

USPTO PatentsView assignee record - 610 granted patents across 103 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

RSS updates for this company

The verdict

According to USPTO PatentsView, Roche ranks #750 of 49,997 tracked US assignees by granted-patent volume, with 610 patents across 103 technology areas.

#750
of 49,997 US assignees by volume
Top 3%
by Innovation Score (62.0/100)
17.2
avg claims per patent
-22%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R750 · US Corporation #750 · 610 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MID 610 grants
  • TOP-DECILE #750/49,997
  • PHOTO-FINISH Renault S
  • CPC-WIDE A61B · 103 areas
  • INNOV-STRONG 62.0/100
  • CLAIMS-RICH 17.2 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -22% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Renault S.A.S. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Roche

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Roche's Innovation Score is 62.0/100 (top 3% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Roche's grant cadence moved

Between 2020–2024, Roche Diabetes Care, Inc. received 256 grants versus 328 in 2015–2019 (-22% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2016 at 84 grants and bottomed in 2015 at 33. Lead class A61B accounts for 50.2% of the portfolio across 103 subclasses. Volume neighbours: Ford Motor Company (#746) and GE Aviation Systems Limited (#754).

Roche's three-year grant acceleration

From 2019–2021 to 2022–2024, Roche Diabetes Care, Inc. moved from 202 to 135 grants (0.67x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,249. See the growth leaderboard.

Who files at Roche's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Roche holds 610 patents at rank #750, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Roche

By rank, the assignees closest to #750 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Roche's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Roche, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (62 here).

Similar claim depth

Nearest assignees by average claims per patent (17.2 here).

Roche's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

62 Top 3% higher than 97% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

20406080100 20152016201720182019202020212022202320242025 26
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Roche Diabetes Care, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 33 5.4%
2016 84 13.8%
2017 60 9.8%
2018 70 11.5%
2019 81 13.3%
2020 61 10.0%
2021 60 9.8%
2022 54 8.9%
2023 37 6.1%
2024 44 7.2%
2025partial year 26 4.3%

Which technologies does Roche Diabetes Care, Inc. patent most?

Top 15 of 103 technology areas

Where it ranks

Overall rank by patents

#750

of 49,997 tracked assignees

Innovation Score

62.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Roche Diabetes Care, Inc.'s patent record in context - here's where to go next.

  • Roche Diabetes Care, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 50.2% of its portfolio - see every assignee active in that class. Explore A61B
  • Ranked #750 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Roche Diabetes Care, Inc. against Ford Motor Company, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 62.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.